- Home
- KLTR vs TLSI Comparison
KLTR vs TLSI Comparison
Compare KLTR & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KLTR
- TLSI
- Stock Information
- Founded
- KLTR 2006
- TLSI 2010
- Country
- KLTR United States
- TLSI United States
- Employees
- KLTR N/A
- TLSI N/A
- Industry
- KLTR EDP Services
- TLSI Medical Specialities
- Sector
- KLTR Technology
- TLSI Health Care
- Exchange
- KLTR Nasdaq
- TLSI Nasdaq
- Market Cap
- KLTR 389.2M
- TLSI 124.9M
- IPO Year
- KLTR 2021
- TLSI N/A
- Fundamental
- Price
- KLTR $2.15
- TLSI $4.69
- Analyst Decision
- KLTR Buy
- TLSI Strong Buy
- Analyst Count
- KLTR 2
- TLSI 6
- Target Price
- KLTR $2.25
- TLSI $11.75
- AVG Volume (30 Days)
- KLTR 704.1K
- TLSI 36.4K
- Earning Date
- KLTR 02-20-2025
- TLSI 11-14-2024
- Dividend Yield
- KLTR N/A
- TLSI N/A
- EPS Growth
- KLTR N/A
- TLSI N/A
- EPS
- KLTR N/A
- TLSI N/A
- Revenue
- KLTR $177,586,000.00
- TLSI $26,891,000.00
- Revenue This Year
- KLTR $3.34
- TLSI $60.96
- Revenue Next Year
- KLTR $1.88
- TLSI $53.65
- P/E Ratio
- KLTR N/A
- TLSI N/A
- Revenue Growth
- KLTR 1.62
- TLSI 67.90
- 52 Week Low
- KLTR $0.76
- TLSI $3.50
- 52 Week High
- KLTR $2.82
- TLSI $10.42
- Technical
- Relative Strength Index (RSI)
- KLTR 47.46
- TLSI 51.68
- Support Level
- KLTR $1.93
- TLSI $4.72
- Resistance Level
- KLTR $2.82
- TLSI $5.32
- Average True Range (ATR)
- KLTR 0.18
- TLSI 0.31
- MACD
- KLTR -0.05
- TLSI 0.01
- Stochastic Oscillator
- KLTR 24.72
- TLSI 47.52
About KLTR Kaltura Inc.
Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and at school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments which are Enterprise, Education, and Technology, and Media and Telecom. The majority of the revenue is derived from Enterprise, Education & Technology. The majority of the revenue is earned from the United States.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.